论文部分内容阅读
脑梗死是当今世界威胁中老年人生命与健康的常见病、多发病,已经有确切的证据表明急性脑梗死患者应用重组组织型纤溶酶原激活物(rtPA)溶栓治疗,不仅可以显著减少患者严重残疾的危险性,而且能够改善患者的生存质量。目前临床影像学的进步推动了rtPA的应用,降低了出血转化的风险,但在临床的实际工作中仍有一些患者由于发生了颅内出血(ICH),限制了后续的抗栓治疗,使得神经功能恢复不佳,甚至超过了溶栓治疗的益处。人们由于担心rt-PA溶栓治疗可能带来脑出血这一严重的并发症,因而往往在治疗方
Cerebral infarction is a common and frequently-occurring disease that threatens the life and health of the elderly in today’s world. There is definite evidence that thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) in patients with acute cerebral infarction can not only significantly reduce Patients with severe disability risk, but also to improve the quality of life of patients. At present, the progress of clinical imaging promotes the application of rtPA and reduces the risk of hemorrhagic transformation. However, in clinical practice, some patients still have limited intracranial hemorrhage (ICH) Poor recovery, even beyond the benefits of thrombolytic therapy. People are worried about rt-PA thrombolytic therapy may lead to cerebral hemorrhage of this serious complication, which is often in the treatment side